Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,122 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Treatment B- Part 1 Clear all
Completed Phase 2 Interventional

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

NCT04736173
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Interventions
Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Electrophysiological Effects of Potential QT Prolonging Drugs

NCT05716854
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

NCT06615570
View directory record Official record
Conditions
Pain
Interventions
VX-973, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants

NCT04949269
View directory record Official record
Conditions
Healthy Participants
Interventions
Deucravacitinib, Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of LY3154207 in Healthy Participants

NCT03942029
View directory record Official record
Conditions
Healthy
Interventions
LY3154207 Capsule, LY3154207 Tablet, Placebo, Fluconazole Tablet
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 22, 2026, 10:06 PM EDT
Terminated Phase 2 Interventional Results available

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

NCT03901469
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
ZEN003694, Talazoparib
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Gilbert, Arizona • Atlanta, Georgia • Westwood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling, AZD9291, Itraconazole
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
San Diego, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 22, 2026, 10:06 PM EDT
Completed No phase listed Observational

Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy

NCT01516866
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 22, 2026, 10:06 PM EDT
Recruiting No phase listed Observational

Genomic Profiling in Cancer Patients

NCT01775072
View directory record Official record
Conditions
Solid Tumors, Hematologic Cancers
Interventions
molecular profiling of tumors, Clinical Germline Analysis
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
18
States / cities
Bridgeport, Connecticut • Hartford, Connecticut • Norwalk, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

NCT02402920
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm
Interventions
Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy
Drug · Other · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 22, 2026, 10:06 PM EDT
Active, not recruiting Phase 2 Interventional

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267
View directory record Official record
Conditions
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 10:06 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib, Daratumumab - 16mg/kg, Bortezomib (BTZ), Daratumumab- 1800mg
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
58
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

NCT05106309
View directory record Official record
Conditions
Schizophrenia
Interventions
10 mg CVL-231 as IR formulation, 30 mg CVL-231 as slow-release MR formulation, 30 mg CVL-231 as medium release MR formulation, 30 mg CVL-231 as fast release MR formulation, 30 mg CVL-231 Target Release, Fasted, 30 mg CVL-231 Target Release, Fed
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

NCT04585789
View directory record Official record
Conditions
Hepatitis B
Interventions
JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional

Computerized Alcohol Misuse Intervention System for Health Care

NCT02368899
View directory record Official record
Conditions
Alcoholism
Interventions
Computerized Alcohol Misuse Intervention, Attention Control (AC)
Other
Lead sponsor
Research Circle Associates, LLC
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

NCT06226454
View directory record Official record
Conditions
Pain
Interventions
VX-993, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT00989586
View directory record Official record
Conditions
Lymphoma
Interventions
milatuzumab, veltuzumab, Correlative/Special Studies, Quantitative T-, B-, and NK cell subsets, Pharmacokinetics, Human Anti-Human Antibodies, veltuzumab and milatuzumab
Biological · Procedure
Lead sponsor
Beth Christian
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults

NCT06106009
View directory record Official record
Conditions
Healthy
Interventions
PF-07976016, Placebo, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 22, 2026, 10:06 PM EDT
Terminated Phase 1 Interventional Results available

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

NCT02669264
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
ADCT-402
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
La Jolla, California • New Haven, Connecticut • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

NCT02323334
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease
Interventions
LY3202626, Placebo (Part A, B, C), Itraconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 22, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

NCT02279095
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene dose level 1, Palovarotene dose level 2, Palovarotene dose level 3, Palovarotene dose level 4
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 22, 2026, 10:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

NCT07701941
View directory record Official record
Conditions
Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
Interventions
Patritumab deruxtecan, Trastuzumab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 10:06 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants

NCT04131556
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Maribavir
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 22, 2026, 10:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

NCT07079631
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 10:06 PM EDT